Revista Farmabiotec - Número 20

#20 farmaBIOTEC 85 • [7] R. Vidaurre et al., "Design of greener drugs: aligning parameters in pharmaceutical R&D and drivers for environ - mental impact", Drug Discov. Today, vol. 29, n.o 7, p. 104022, jul. 2024, doi: 10.1016/j.drudis.2024.104022. • [8] N. Puhlmann, E. Abbate, K. Kümmerer, A. G. Oomen, A. M. J. Ragas, y C. Moermond, "Applicability of the European Commission’s framework on safe and sustainable by design to the pharmaceutical sector", Sustain. Chem. Pharm., vol. 42, p. 101845, dic. 2024, doi: 10.1016/j.scp.2024.101845. • [9] M. Miettinen, " “By Design” and Risk Regulation: Insights from Nanotechnologies", Eur. J. Risk Regul., vol. 12, n.o 4, pp. 775-791, dic. 2021, doi: 10.1017/err.2020.58. • [10] "ICH Q8 (R2) Pharmaceutical develop - ment - Scientific guideline | European Medicines Agency (EMA)". Accedido: 14 de julio de 2025. [En línea]. Disponible en: https://www.ema.europa.eu/en/ ich-q8-r2-pharmaceutical-development-scientific-guideline • [11] A. Hernandez-Vivanco, V. Vlaisavljevic, L. Gonzalez- Moragas, y M. Santana, "Quality-by-design as the pharma- ceutical innovation paradigm: mapping the field and pro - posing a conceptual framework", Technol. Forecast. Soc. Change, vol. 217, p. 124182, ago. 2025, doi: 10.1016/j. techfore.2025.124182. • [12] J. S. Srai, T. S. Harrington, N. R. Joglekar, y S. Narayanan, "Convergence of Product, Production, and Supply Chain Design Rules: Evidence From Pharmaceutical Pre‐ Competitive Collaboration Networks", J. Oper. Manag., vol. 71, n.o 3, pp. 314-334, abr. 2025, doi: 10.1002/joom.1352. • [13] M. J. Cobo, A. G. López-Herrera, E. Herrera-Viedma, y F. Herrera, "SciMAT: A new science mapping analysis soft- ware tool", J. Am. Soc. Inf. Sci. Technol., vol. 63, n.o 8, pp. 1609-1630, ago. 2012, doi: 10.1002/asi.22688. • [14 S. Merriam, Qualitative research: a guide to design and implementation. Hoboken, NJ, USA: Sage, 2009. • [15] M. B. Miles y A. M. Huberman, Qualitative data analy- sis: An expanded sourcebook. SAGE, 1994. • [16] A. M. Dias, A. M. Carvalho, y P. Sampaio, "Quality 4.0: literature review analysis, definition and impacts of the digi - tal transformation process on quality", Int. J. Qual. Reliab. Manag., vol. 39, n.o 6, pp. 1312-1335, may 2022, doi: 10.1108/ ijqrm-07-2021-0247. • [17] P. Suriyaamporn, B. Pamornpathomkul, P. Patrojanasophon, T. Ngawhirunpat, T. Rojanarata, y P. Opanasopit, "The Artificial Intelligence-Powered New Era in Pharmaceutical Research and Development: A Review", AAPS PharmSciTech, vol. 25, n.o 6, ago. 2024, doi: 10.1208/ s12249-024-02901-y. • [18] A. Hernandez-Vivanco, M. Bernardo, y C. Cruz- Cázares, "Sustainable innovation through management sys- tems integration", J. Clean. Prod., vol. 196, pp. 1176-1187, sep. 2018, doi: 10.1016/j.jclepro.2018.06.052. • [19] K. Iatridis y E. Kesidou, "What Drives Substantive Versus Symbolic Implementation of ISO 14001 in a Time of Economic Crisis? Insights from Greek Manufacturing Companies", J. Bus. Ethics, vol. 148, n.o 4, pp. 859-877, abr. 2018, doi: 10.1007/s10551-016-3019-8. Calidad por diseño Figura 2. Marco conceptual del rol de QbD en la transición gemela. Fuente: elaboración propia.